Celsius Therapeutics

Provider of single-cell RNA and genomic analysis

placeCambridge, Massachusetts, United States calendar_todayFounded 2018 groups50 employees language celsiustx.com

Registered entities

Innovation

1 patent family — focus: Chemistry & metallurgy; filing pace active. Cited 66 times.

YearFilings
20241
20251
20261

Investor mix

13 investors on record; lead investors include Third Rock Ventures, Casdin Capital; 1 has since exited.

Investor typeCountShare
Venture capital1077%
Other / undisclosed323%
Coming soon